Cargando…
Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder
BACKGROUND: Up to 80% of reproductive-aged women experience premenstrual symptoms. Premenstrual Dysphoric Disorder (PMDD) is a severe form, affecting 2-5% of women. Combined oral contraceptive pills (COCPs) are used in the treatment of PMDD. Clinical practice suggests that a newer COCP containing no...
Autores principales: | Robertson, Emily, Thew, Caroline, Thomas, Natalie, Karimi, Leila, Kulkarni, Jayashri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498579/ https://www.ncbi.nlm.nih.gov/pubmed/34630323 http://dx.doi.org/10.3389/fendo.2021.704488 |
Ejemplares similares
-
Nomegestrol acetate-17b-estradiol for oral contraception
por: Burke, Anne
Publicado: (2013) -
Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
por: Breech, Lesley L, et al.
Publicado: (2010) -
Childhood adversity predicts stronger premenstrual mood worsening, stress appraisal and cortisol decrease in women with Premenstrual Dysphoric Disorder
por: Nayman, Sibel, et al.
Publicado: (2023) -
Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives
por: Rapkin, Andrea J, et al.
Publicado: (2019) -
The Cerebellum and Premenstrual Dysphoric Disorder
por: Rapkin, Andrea J., et al.
Publicado: (2014)